BRIEF

on SENSORION (EPA:ALSEN)

Sensorion to Present at ASGCT Annual Meeting

Stock price chart of SENSORION (EPA:ALSEN) showing fluctuations.

Sensorion, a biotechnology firm specializing in hearing loss therapies, announced its participation in the American Society of Cell and Gene Therapy's 28th Annual Meeting. The event will be held in New Orleans from May 13 to 17, 2025. During the meeting, Sensorion will present two significant posters on May 15.

The first poster, numbered 1556, will focus on the safety and efficacy of GJB2-GT, an adeno-associated viral vector-based gene therapy treatment for DFNB1A, a common form of hereditary deafness. The second poster, numbered 1559, will explore the GJB2 gene therapy response in pre-clinical mouse models of this condition. This latter poster is a collaboration with Professor Christine Petit from the Hearing Institute, Institut Pasteur.

R. H.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all SENSORION news